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Tiivistelmä Referat – Abstract
Toisen  sukupolven  sekvensointilaitteet  tuottavat  huomattavan  suuren  määrän  sekvenssiä  lyhyessä 
ajassa  verrattuna  ensimmäisen  sukupolven  laitteisiin.  Taustaosassa  annetaan  yleiskuva  eri  toisen 
sukupolven sekvensaattorien toimintamenetelmistä. Tarkemmin paneudutaan Illumina Genome Analyzer 
II laitteeseen, jolla tuotettiin sekvenssit tätä tutkielmaa varten.
Tällä  tutkielmalla  on  kaksi  tavoitetta.  Ensimmäinen  tavoite  on  tehdä  analyysiohjelmisto  genomista 
sekvensointia varten. Toinen tavoite on käyttää tätä ohjelmistoa vertailemaan ihmisen kaikkien geenien 
eksonien sekvensointimenetelmiä kahdelta eri valmistajalta, Roche Nimblegeniltä ja Agilentilta.
Materiaali ja metodi osassa kuvataan ohjelmiston toiminta tarkemmin. Kaikista ohjelmistolle annettavista 
tiedostoista on kuvaus sekä esimerkki. Ohjelmisto linjaa sekvensointilaitteen tuottamat lyhyet sekvenssit  
vertailugenomia  vastaan,  etsii  linjauksesta  varioivia  kohtia  ja  antaa  tietoa  miten  tuotetut  sekvenssit  
kattavat  suunnitellut  genomialueet.  Lisäksi  tulostiedostot  sisältävät  sekvenssiparien  poikkeavuuksia, 
suurempien sekvenssin lisäyksen tai poiston auheuttavia muutoksia ja yritetään yhdistellä ei linjattuja 
sekvenssejä isommiksi osiksi. Sekvensointi paketit eri valmistajilta myös esitellään ja tehdyt muutokset 
valmistajien  suosittamiin  ohjeisiin   listataan.  Viimeisenä  osana  käydään  läpi  työssä  käytettyjen 
ohjelmistoajoille annetut tiedostot sekä muut niihin liittyvät muutokset.
Analyysiohjelmiston  tuloksena  tuotetaan  perustason  analyysi  sekvenssoinnista  sekä  sen  laadusta. 
Kaikki  tulostiedostot  selitetään  käyttäjälle.  Tulosten  perusteella  voi  käyttäjä  sitten  tehdä  syvempää 
analyysia oman projektinsa tarpeiden mukaan.
Eksomivertailussa  Nimblegenin  sekvensointimenetelmä  näyttäisi  olevan  parempi  kohdealuen 
sekvensointiin  sekä  omalla  että  itsenäisellä  aluemäärittelyllä.  Agilentin  menetelmä  tuotti  laajemman 
yksinkertaisen sekvenssipeiton ihmisgenomin eksoneihin, mikä kuitenkin on liian vähäinen luotettavaa 
variaatioiden  tunnistamista  varten.   Nimblegenin  menetelmä  sen  sijaan  kattoi  enemmän tavoiteltuja 
sekvenssialueita  kun  vaadittiin  variaatioiden  tunnistamiseen  riittävä  sekvenssipeitto  (vähintään  10 
sekvenssiä). Nimblegenin menetelmä tuotti myös vähemmän virheellisiä sekvenssipoikkeavuuksia.
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Tiivistelmä Referat – Abstract
The next-generation sequencing (NGS) platforms create a large amount of sequence in short amount of 
time, when compared to first generation sequencers. An overview of the NGS platforms is provided with  
more in-depth look into Illumina Genome Analyzer II as that is used to create the data for the thesis.
There were two main aims in this thesis.  First,  to create a pipeline which can be used to analyse  
genomic sequencing. Second, to use the pipeline to compare whole human exome capture methods 
from two manufacturers, Roche Nimblegen and Agilent.
The pipeline is describe in detail in material and methods. All the inputs for the pipeline are described 
and  examples  shown.  In  the  pipeline  the  given  sequences  are  first  aligned  against  the  reference 
genome.  Then  various  separate  analysis  is  performed  to  retrieve  variants  and  coverage  of  the 
sequencing.  Supplementary  results  include  paired-end  anomalies,  larger  insertion  and  deletion 
polymorphisms and assembly of non-aligned sequences. The two capture methods are also described 
and  changes to  the  manufacturers'  recommended  protocols  are  listed.  Finally,  the  section  has  the 
options and various inputs used in the pipeline runs of the exome data.
The results of the pipeline is a basic level  of analysis of  the sequencing as well  as various graphs 
showing the quality of the run. All the output files intended for user are described. By using the results of 
the pipeline, the user can do more in-depth analysis as required by the project. 
When comparing  the  two  exome capture  methods,  the  Nimblegen capture  was  shown  to  be  more 
efficient in capturing the CCDS exome.  While the Agilent capture  kit provided better one fold coverage 
over the exome, higher fold coverage (over 10 fold), which is required for reliable variant calling in next-
generation sequencing, was better reached using the Nimblegen capture kit. Also, significantly fewer 
false  positive  paired-end  anomalies  were  observed  in  the  library  created  by  using  the  Nimblegen 
capture.
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Chapter 1
Introduction
The thesis is about creating a variant calling pipeline for paired-end sequencing
data from Illumina Genome Analyzer II using paired reads and then using it for
comparison of two exome analysis kits. However the pipeline would work for any
other sequencer using paired reads; so it’s not attached as such to any particular
sequencing platform.
1.1 Next Generation Sequencing
Sanger sequencing was invented in the 1977 by Sanger and Coulson (Sanger et al.,
1977). The automated version of Sanger sequencing is considered to be first genera-
tion sequencing with the ideas springing up at the end of 1980 (Zimmermann et al.,
1988). In last few years next-generation sequencing (NGS) platforms have taken
over most of the large scale sequencing tasks. Sanger sequencing is still considered
to be the gold standard, but the costs are one dollar per kilobase which means that
most laboratories cannot afford to use it for large scale sequencing needs. The speed
of data generation is also too slow for a large scale sequencing, as the latest auto-
mated Sanger sequencers create about 14 million base pairs of sequence per week if
run 24 hours per day.
NGS platforms create a lot more data at lower cost per nucleotide than first
generation machines. On average, the current available platforms create 25 gigabases
of sequence per week. The latest machines increase the data generation ten fold.
NGS platforms have enabled many of the older methodologies to be replaced by
sequencing due to be widening of scope or by enhancing accuracy, invention of
whole new areas and required development of new algorithms to handle the amount
of data produced.
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There are six manufacturers for NGS sequencers, most used ones being: Illu-
mina with Illumina Genome Analyzer, Roche with 454 and Applied Biosystems
with SOLiD.
There is no single chemistry by which the NGS machines work as there was with
first generation machines. They all share some general steps but proceed to do them
in a variety of ways (Voelkerding et al., 2009; Metzker, 2010). The steps are
1. Template Preparation
2. Sequencing and Detection
3. Data Analysis
1.1.1 Template Preparation
In template preparation the target DNA is first fragmented into smaller pieces,
which are called fragment template or mate-pair template, and then attached to a
solid surface. This immobilisation allows thousands to billions of sequencing events
to be performed simultaneously as they are physically separated from each other.
However in the case of Pacific Biosciences an enzyme instead of DNA fragments is
attached to the solid surface.
There are two methods for template preparation.
Clonally amplified templates
The fragment template used in this method is amplified to have millions of copies.
These can be affixed to beads or a solid surface, depending on the platforms used.
The most common being emPCR and solid-phase amplification.
In emPCR, the fragments are captured to beads in which the amplification is
done. After that the beads are attached to support which varies between the manu-
facturers. In solid-phase amplification, the fragments are attached to a solid-surface
directly and amplified. Clonally amplified templates have problems with dephasing,
where some probes get out of sync in sequencing, causing different nucleotides to be
attached.
This method is being used by the Illumina GA II (Illumina Incorporated, CA,
USA) with solid-phase amplification and by Applied Biosystems SOLiD (Life Tech-
nologies Corporation, CA, USA) with emPCR.
Single-molecule templates
In this method, no amplification is required. There are three different methods
used with single-molecule templates. In first method, the primers are attached to a
2
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solid-surface. Then by adding adapters the fragments are hybridized to the attached
primers. In second method, the fragments are attached to the surface by priming
and extending single-stranded, single-molecule templates from immobilized primers.
In the third method, an enzyme instead of a primer or fragment is attached to a
solid surface.
This method is being used by Helicos HeliScope (Helicos BioSciences Corpora-
tion, MA, USA).
1.1.2 Sequencing and Detection
The sequencing techniques are linked with detection and imaging of the result. There
are several methods used in sequencing.
Cyclic reversible termination (CRT)
This method works by adding nucleotides that terminate the DNA synthesis. In
each cycle a single nucleotide is added, then an image taken and finally termination
is reversed. The nucleotides are modified with reversible termination and labeled
with fluorescent label. There are several ways how the termination is done with each
manufracturer using their own system. This method also requires a modified DNA
polymerase which has spurred development and solutions have been suggested to
overcome this.
CRT uses either one or four colour labels which affects the image analysis. With
the four colour system, the image shows which positions added a label. With one
colour system, the image shows if a given position added a colour or not.
This method is being used by the Illumina GA II with four colour labels.
Sequencing by ligation
The method is run in two cycles: ligation cycle and primer reset cycle. First an
universal primer is hybridized to the library fragment as part of primer cycle. In
each ligation cycle, a set of four fluorecently labeled di-base probes are allowed to
hybridize to the fragment. Once the probes are hybridized, the universal primer and
probe next to it are ligated together by DNA ligase. After detection the fluorescent
label is cleaved off and the next ligation cycle is commenced. After all the ligation
cycles are done the primer is reset and new ligation cycles are done. Each ligation
cycle detects every 5th base of the fragment and as the primer reset moves the primer
by one base, 5 primer reset cycles are needed to cover the all bases the produced
read.
This method is being used by the Applied Biosystems SOLiD.
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Single-nucleotide addition
This is also called Pyrosequencing. In this method, nucleotides are added one at a
time with DNA polymerase, but no modified nucleotides are involved. In addition,
no fluorescent markers is used; instead the release of phosphorus in nucleotide poly-
merisation is converted into light by a series of enzymatic reactions. This requires
the intensity of the light to be measured. The intensity of the signal, measured
after each added nucleotide, shows if and how many of that particular nucleotide is
attached.
This method is being used by the Roche 454 (454 Life Sciences, a Roche company,
CT, USA).
Real time sequencing
This is thought to be the next new method with sequencing. The Pacbio RS se-
quencer (Pacific BioSciences, CA, USA), which should be brought to market 2011,
uses real time sequencing. In their method, an enzyme is attached to a surface and
the nucleotides are marked with fluorescent markers. Colour is emitted when it’s
removed from the nucleotide as it’s attached to the DNA strand by the polymerase
enzyme. Result is a graph with intensity of four colours versus time.
1.1.3 Data analysis
A single sequencing run produces two different kinds of data. First is the raw result
comprising of the images or intensities. Usually there is also a software package pro-
vided by the manufracturer which converts the images to sequence fragments. The
amount of the reads and their length depends on the platform and run parameters.
Due to very large amount of data produced by the next-generation sequencers
the handling of results required considerable development over the tools used in
first generation sequencing. In most cases the tools are not memory efficient or fast
enough to handle millions or billions of short reads. For example, classic sequence
alignment tool such as blast could take a week to make alignments of short reads
against the reference sequence. In many cases, completely new algorithms have been
taken into use to overcome these problems.
In addition to the classical de novo sequence assembly, sequencing is nowdays
used for many other applications. For example, microarray-based technologies to
measure relative amounts of transcripts are being replaced with RNA sequencing.
Chromatin immunoprecipition studies and genome-wide profiling of epigenetic mark-
ers are also being done with the new sequencers.
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Figure 1.1: Picture of the Illumina Genome Analyzer IIx with paired-end module
(in left) in FIMM.
1.2 Illumina Genome Analyzer II
The Illumina Genome Analyzer II came to market in 2008. The current platform
is called GA IIx. The Illumina has also put out the more advanced version of the
GA IIx which is based on the same chemistry: HiSeq 1000 and HiSeq 2000. Both
achieve almost 20 fold increase in throughput. The latest addition to the Illumina
sequencing platforms is MiSeq which is smallest of the instruments with smallest
throughput with about 1Gb per day.
In addition to the sequencing machine, there is usually a cluster station and a
paired-end module. The cluster station is needed for the sequencing but one such
a station can serve more than one sequencer. Cluster station is used to generate
clusters as described in section 1.2.2 on page 6. The paired-end module is needed
for being able to read the sequence of a short DNA fragment from both ends of the
molecule. On average a paired-end run of 100 + 100 bps with the Illumina GA II
will take a week or little over, depending on the specifics of the run.
The operational workflow for Illumina GA II has four steps
1. Library preparation
2. Cluster generation
5
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3. Sequencing
4. Data analysis
1.2.1 Library preparation for DNA sequencing
The DNA used in sequencing can be whole genome or targeted areas of interest.
There should be 0.1 - 3 µg of DNA depending of the application. First the DNA
to be sequenced is fragmented (Figure 1.2 A). After fragmentation, the ends are
repaired and a nucleotide A is added as an overhang (Figure 1.2 B) to facilitate the
adapter ligation. Adapters are then ligated to the overhang and the fragments are
amplified by PCR (Figure 1.2 C). Adapters allow the fragments to be amplified with
predefined set of PCR primers.
This takes about 6 hours of which 3 hours is hands-on.
Figure 1.2: Solexa GA II step 1, library preparation (Illumina, GAB, 2010).
1.2.2 Cluster generation
The DNA fragments are first attached or hybridized to a silica slide referred as a
flow cell (Figure 1.3 A). There are 8 separate lanes in a flow cell. This allows 8
separate sequencing events in one run. Each fragment library goes into one lane.
Usually this means that 8 samples are analysed in one run. However multiplexing
kits from Illumina allows up to 12 samples in one lane with total of 92 samples
per flow cell. In Multiplexing, an index tag (a small sequence) is attached to each
sequence fragment which varies between samples. This tag then allows the produced
sequences to be separated per sample. Multiplexing is useful with smaller targets
within large genome or smaller genomes, such as bacteria.
The next step after hybridization is bridge amplification. In bridge amplification,
the second strand is synthethised to the attached fragment using the adapter as
primer. The strands are then separated with denaturation and bound to the adjacent
primer creating a bridge (Figure 1.3 B). This process is repeated 35 times to create
6
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a clusters of clonally amplified DNA molecules also known as sequencing templates
(Figure 1.3 C).
Lastly the reverse strands are removed and the sequencing primers annealed to
the clusters (Figure 1.3 D).
This in total takes about 4 hours with less than 10 minutes hands-on.
Figure 1.3: Solexa GA II step 2, cluster creation (Illumina, GAB, 2010).
1.2.3 Sequencing
The sequencing can be divided into two parts, the sequencing and base calling. Se-
quencing is carried out in three steps. First, a modified nucleotide with a fluorescent
label is added to the primer according to the template fragment. Then an image is
taken, and finally the termination group and fluoropore is cleaved from the added
nucleotide (Figure 1.4 A). This is then repeated to create reads of the wanted length
(Figure 1.4 B). Current chemistry supports up to 150 nucleotide reads. Finally, the
bases are called with computer software (Figure 1.4 C).
Figure 1.4: Solexa GA II step 3, sequencing (Illumina, GAB, 2010).
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In paired end sequencing the second read is done after the first strand is com-
pletely sequenced. First, the newly made strand is removed with denaturation. The
clusters are then redone in a similar fashion as in bridge amplification. The differ-
ence is that the forward strands are then removed instead of the reverse ones (Janitz,
2008). The sequencing of the second strand is done as described above.
This takes from 2 to 7 days (depending on the length of the reads) for single end
runs and 5 to 14 days for paired-end runs with about 30 minutes hands-on time.
1.2.4 Data analysis
Figure 1.5: GA II image. A section of an image from the Illumina GA II for one
nucleotide in sequencing. Each white dot represents a cluster.
The Illumina GAII generates images as the raw data. These images are tiff (Adobe,
TIFF v6.0 specification, 2010) files and there is one file for each nucleotide for each
cycle. An example of the image that is created is shown in figure 1.5. These im-
ages are automatically converted into sequences using Illuminas real time analysis
software. This produces the sequences which are then converted into fastq file for-
mat (Cock et al., 2009). For single-end sequencing runs there is one file and for
paired-end runs there are two.
8
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In an average run there are between 2 to 16 Gb (in hard drive space) and from
2 to 8 Gb (in base pairs) of sequences are produced per lane with each having from
40 to 120 million reads. The numbers vary very much due to cluster density, read
length and whether paired-end sequencing is used.
1.3 Whole Genome Exome Kits
With current NGS platforms, sequencing of the whole genome or targeted parts of
it has been enabled. One of the latest developments are the exome kits. These allow
targeted capture and sequencing of the whole human exome. Currently there are five
kits for sequencing human exomes, two produced by Nimblegen (Roche Nimblegen
Inc, WI, USA), two by Agilent (Agilent Technologies Inc, CA, USA) and one by
Illumina. In this experiment the first kits by Nimblegen and Agilent are used.
Definition of the whole exome however is not entirely clear. Exome should be all
exons in the genes of the organism, in this case human. Not all genes locations are
known however so different databases such as EnsEMBL, NCBI RefSeq and UCSC
show a bit different set of genes. Creating an exome from these would have differ-
ences. Both exome kits are designed against Consensus Coding Sequence (CCDS)
(Pruitt et al., 2009) for human genome version 18 (hg18).
1.3.1 Nimblegen SeqCap EZ Exome Library
The Nimblegen SeqCap EZ kit has 2.1 million DNA probes with length of 60 to 90
basepairs. On average over 10 probes per exon in the human genome, to capture
DNA fragments representing the exons by hybridization. The SeqCap Ez is designed
to be simple to use, as all probes are in one tube. It also includes some built-in
controls to evaluate the quality of the capture and sequencing in the lab (Nimblegen,
Exome brochure, 2010). The SeqCap Ez needs from 1 to 5 µg of input library.
Performance of the kit is shown by nimblegen in table 1.1.
1.3.2 Agilent SureSelect Human All Exon Kit
The Agilent SureSelect kit is aimed to cover the entire human exome (Agilent, Exome
brochure, 2010). The speficifications state that it covers 38Mb or 1.22% of human
genome corresponding to all consensus coding sequence regions (Pruitt et al., 2009).
Agilent uses 120 basepair long RNA probes. This kit is also packed into a single
tube like Nimblegens SeqCap Ez. However it is noted that only 500 ng of prepared
sequence library or from 1 to 3µg of genomic DNA is required. Several alternative
9
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sizes of the kit are available, from 5 to 5000 reactions. Performance of the kit is
shown by agilent in figure 1.6.
1.4 Other NGS Pipelines
Currently there are not that many pipelines available in the literature or otherwise.
In some cases it is most likely considered to be part of infrastructure, and thus not
published or put on websites. For example, the Sanger Institute has its own similar
pipeline, but nothing can be found on their website.
A Genome Analysis Toolkit known as GATK (Genome Analysis Toolkit, 2010)
has been developed by the Broad Institute in the USA. GATK is a software library
for developing tools to make analysis of NGS data simpler. However, since it is not
a pipeline nor a tool as such, it is not being used in the produced pipeline. Some of
steps, such as variant and indel calling, in the pipeline described in this thesis could
alternatively be conducted using GATK.
There is a one published pipeline for NGS from 2009 (Jex et al., 2010). How-
ever, this pipeline is aimed at mitochondrial DNA and assumes certain methods in
sequencing. Thus, it is not really usable for our needs.
A pipeline called inGAP also exists (Qi et al., 2010). It uses similar tools as this
pipeline. However, inGAP is missing some of the functionalities such as statistics
and paired-end anomaly detection which are available in our pipeline. inGAP has
some extra flexibility, such as supporting single reads.
There are several commercial software packages which are able to perform variant
calling, such as NextGENe (NextGENe, 2010) and Alpheus (Alpheus, 2010). How-
ever, there might be a need for the user to run the pipeline with different options,
or hardware configurations could change. In many cases licensing restrictions may
exist in proprietary software packages that can easily hamper the practical use. For
this reason, while proprietary software packages can be useful, they do not remove
the need for this pipeline.
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Table 1.1: Performance of Seq Cap Ez as provided by Nimblegen (Nimblegen, Exome
brochure, 2010).
Figure 1.6: Performance of SureSelect capture as provided by Agilent (Agilent,
brochure, 2011). The data shown has been done using SureSelect human X chromo-
some baits and not all exon capture.
11
Chapter 2
Aims
The thesis will have two aims. Developing of a functional pipeline for variant call-
ing is the first aim. Second aim is to use the pipeline for comparing two Exome
sequencing kits, available from two manufacturers.
2.1 The pipeline
The developed pipeline aims to 1) provide basic information about the quality of
experiment, 2) do the alignment of the sequencing products to the reference, 3) iden-
tify SNP and copy-number variants (CNV), 4) annotate known and novel variants
and 5) identify anomalies.
2.2 Exome kit comparison
The aim in exome comparison is to see how well the kits perform in sequencing
the human exome. Coordinates provided by both manufacturers were compared to
the reference exome (Pruitt et al., 2009). Sequencing results of the libraries created
from the two sequence capture kits were evaluated by several means such as coverge
through the exome with several target sets as well as whole transcripts or genes,
ability to indentify known and novel variants and how much variability the pairing
showed.
12
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Materials and Methods
This chapter shows the detailed explanation of the pipeline itself. The pipeline
has two parts which are executed separately: indexing and variant calling pipeline
(VCP). The indexing is a separate section where pre-processing is done based on the
reference sequence. This is required before the pipeline can be executed as various
steps, most notably alignment, use the indexes created. In the thesis the different
parts of the VCP are described in different sections.
Different sections of the pipeline are shown in the graphs of this chapter. In those
graphs the boxes represent data while the ellipses represent a program to be run.
Note that not all the files created are represented in graphs, but only the ones which
are considered to be important. Arrows are used to connect programs showing that
first programs output is the second ones input.
Most of the programs used here are publicly available. In addition, several scripts
have been developed to make the pipeline run automatically. Most of these have
been written with perl scripting language, but some are done with R and bash.
The original plan of the pipeline was designed by Pekka Ellonen from FIMM
Technology Centre.
3.1 The pipeline overall
The pipeline sections and their main inputs and outputs are shown in figure 3.1.
The workflow is currently executed with a python script. The script is able to
restart the workflow from the middle of the workflow if something fails or if an
option is modified and workflow rerun. At the start of the pipeline, the versions of
external programs used are printed out. During the run the pipeline does some clean
up to the files produced. Larger of the intermediate files are removed, except the
13
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alignment results which are saved. Some of the larger result files are also compressed
using gzip program.
For indexing, the inputs are given on command line as the indexing only needs the
reference sequence file. For the VCP, the inputs to are given with a configuration file.
The configuration file has three sections. First section lists all the input files used
by the pipeline as well as output directory. Second section lists selected options for
tools within the VCP. Third section has limits and options which affect the pipeline
instead of an individual program.
The configuration file for the pipeline can be seen in appendix A on page 63.
Pipeline inputs
The main input files for the VCPipeline are: the reference sequence and the two
paired-end reads. In addition, the VCPipeline can use a target area, a SNP infor-
mation and an exon position files, but these are not required.
The reference sequence should be in fasta file format. Fasta format is simple
format in which the sequence entry has a header line starting with a > character.
After header it has one or more lines with the sequence. The suggestion is to have up
to 60 characters of sequence in one line. Multiple sequence entries can be in a single
file. However, the indexing for alignment uses only part of the name, stopping at
the first space. This part before the space must be unique so that the index created
is valid. The part will be used as the reference item name of the sequence entry in
the pipeline. The resulting item name should be same as what is used in possible
additional inputs in order for them to match the results of the pipeline. The order
of the items in the reference sequence file defines some of the sorting at some points
later on, for example order of reference items in anomaly plots.
@HWI-EAS418_0100:1:1:1:1553#0/1
NGACTCCAAGCAAACTCCACATGCAGGCAATGGAACTTAACANNNCNNNCAGCGGGAAG
+HWI-EAS418_0100:1:1:1:1553#0/1
DMVUSXVRRUTNTPPPXWQSROWWRBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
@HWI-EAS418_0100:1:1:1:282#0/1
NGTTGAAAGCTATGGTACAATATGCAAAGTCTCTTAGTGAAGNNNTNNNAAAATCAACA
+HWI-EAS418_0100:1:1:1:282#0/1
DN[[Y[[ZYY[SWZWUYY[[[[[[[VUVVVY[ZBBBBBBBBBBBBBBBBBBBBBBBBBB
@HWI-EAS418_0100:1:1:1:720#0/1
NTGACGTTCTACACTTCCAGTGTCTGATCCGGAGTGTTGCTCNNNTNNNTCATCCCCAC
+HWI-EAS418_0100:1:1:1:720#0/1
DPUUXVWWXTPUUWXWXXWWWXXWWWSWWWUTBBBBBBBBBBBBBBBBBBBBBBBBBBB
Figure 3.2: An example from the start of a fastq file produced by Illumina software
from the GA II paired-end sequencing. This example is from the Agilent exome
comparison data.
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The paired-end read files should be in fastq file format (Cock et al., 2009). There
should be two files with one file having one end of the pairs and the other having the
other end of the pairs. An example of start of a fastq file can be seen in figure 3.2.
Target area should be gff file format (GFF specification, 2010). This is assumed
to be target of the sequencing and there will be additional information regarding this
area in the coverage section of the pipeline. The track names given are not checked
so this file can only have the areas which are relevant to the target. An example of
the file can be seen in table 3.1. The file should be sorted by the position (first by
start point, then by end point) in the reference entry so each reference entry is in
its own section. The target areas can overlap, but a target area cannot be within
another target area.
The SNP information file is a tab separated file without a header row. This
file should have one sequence variant in each row. The file should be sorted by the
position in the reference entry in a similar fashion as the target area file above. The
same position in the reference can have multiple entries and names of the SNPs
do not have to be unique. An example of the SNP information file can be seen in
table 3.2.
The exon position file is also a tab separated file without a header row. This file
has position of all exons in the reference genome and gene, transcript and protein
information related to the exon. It should be sorted by the position in reference
entry in a similar fashion as the target area file above. There is no unique restrictions
outside of the ordering. An example of the exon position file can be seen in table 3.3.
3.2 Indexing
Figure 3.3: Steps of index creation for the pipeline.
The indexing is a separate part of the entire pipeline and its workflow is shown
in the figure 3.3. It must be run every time the reference sequence changes and must
16
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Table 3.1: The target area file
This is in gff file format (GFF specification, 2010). The data is from CCDS (Pruitt
et al., 2009) target areas used in exome comparison.
1 bed2gff feature133814 69091 70008 0 + . group133814;
1 bed2gff feature133815 367659 368597 0 + . group133815;
1 bed2gff feature133816 621096 622034 0 + . group133816;
1 bed2gff feature133817 861322 861393 0 + . group133817;
1 bed2gff feature133818 865535 865716 0 + . group133818;
1 bed2gff feature133819 866419 866469 0 + . group133819;
1 bed2gff feature133820 871152 871276 0 + . group133820;
1 bed2gff feature133821 874420 874509 0 + . group133821;
1 bed2gff feature133822 874655 874840 0 + . group133822;
Table 3.2: The SNP information file.
This file can have other similar entries as well and in the exome comparison there
is also CNVs in the file.
First column has the reference entry name (in this case the chromosome number).
Second column has the name of the variant. Third and fourth columns have the
start and end of the variant respectively. If the end is smaller than start then there
is an insert between the two positions. Fourth column has alleles of the variant.
Fifth column has the consequence of the variant.
This data is from the Ensembl (Hubbard et al., 2009) version 57 with variants version
37b.
1 rs55998931 10492 10492 C/T UPSTREAM
1 rs62636508 10519 10519 G/C UPSTREAM
1 rs10218492 10828 10828 G/A UPSTREAM
1 rs10218493 10904 10904 G/A UPSTREAM
1 rs10218527 10927 10927 A/G UPSTREAM
1 rs28853987 10938 10938 G/A UPSTREAM
Table 3.3: The exon position file.
First column has the reference entry name (in this case the chromosome number).
Second and third columns have the start and the end of the exon respectively. Fourth
column has the gene in which the exon belongs to. Fifth column has the transcript
in which the exon exists in and sixth the protein of that trascript. Fifth and sixth
columns can be empty. The same position can have multiple entries allowing the
position to be in multiple genes, transcripts or proteins.
This data is from the Ensembl (Hubbard et al., 2009) version 57.
1 11874 12227 ENSG00000223972 (DDX11L10) ENST00000456328 ENSP00000410013
1 12010 12057 ENSG00000223972 (DDX11L10) ENST00000450305
1 12179 12227 ENSG00000223972 (DDX11L10) ENST00000450305
1 12613 12697 ENSG00000223972 (DDX11L10) ENST00000450305
1 12613 12721 ENSG00000223972 (DDX11L10) ENST00000456328 ENSP00000410013
1 12975 13052 ENSG00000223972 (DDX11L10) ENST00000450305
1 13221 13374 ENSG00000223972 (DDX11L10) ENST00000450305
1 13221 14412 ENSG00000223972 (DDX11L10) ENST00000456328 ENSP00000410013
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be done before running the VCPipeline itself. Indexing consists of three tools: bwa
(Li and Durbin, 2009), samtools (Li et al., 2009) and index2karyotype.pl script.
The bwa is the alignment tool that is used in the VCPipeline. It needs an index
to the reference sequence and bwa index command creates that. In small variants
sections a second index is needed for the samtools tool package. samtools index is
a command which creates the index file required. Lastly the index2karyotype.pl is
executed. It is a script which was created to convert the samtools result for another
tool used in paired-end anomalies part of the pipeline. It takes in the samtools’
index file and reformats it.
Reference sequence is a fasta file which can be have multiple sequence entries.
However one reference sequence cannot be in multiple files.
3.3 VCPipeline - alignment
Bwa
aln
Reference
sequence
Paired end
sequence 1
Samtools
import
Samtools
sort
Paired end
sequence 2
Bwa
aln
Bwa
sampe
Samtools
rmdup
Sorted
Alignment
Samtools
sort
Samtools
view Alignment
filter_B.pl
Figure 3.4: Steps to align the reads to reference in the pipeline.
First step is to do a filtering on quality score B. The Illumina documentation
mentions that with Casava 1.5 onwards the ends of the reads may have a block
B quality scores and that these block should not be used in further analysis. The
filter B.pl script trims the sequences and removes pairs from which one or both
reads end up shorter than the defined minimum (by default 36). Then the actual
alignment to the reference is done and for this bwa is used. The workflow is in
figure 3.4. The alignment is done in 3 steps. First, the individual reads are aligned
to the reference with bwa aln command. The command writes the result in to a
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binary format which marks the coordinates within the reference. Then the individual
reads are paired and written out in sam (Li et al., 2009) formatted alignments file
with bwa sampe command. The result of this is the raw alignment.
Next, the raw alignment is cleaned. First, the raw alignment file is converted to
binary sam (bam) format with samtools import command. Then the bam file is
sorted according to the positions of the alignments in the reference with samtools
sort. The sorting is required for the samtools rmdup command which is executed
next. This removes the possible PCR duplicates created during the sample prepa-
ration. The result of this is the sorted alignment binary file which is used as input
in the small variants section later on.
Last step is to get a name sorted sam file for other sections. To get this the
position sorted binary bam file is re-sorted with samtools sort. This time the
file is sorted by the name of the read, creating a bam file with read pairs next to
each other. Finally, the file is then converted to sam format with samtools view
command.
The alignment tool could be changed with sufficient ease if that was wanted as
long as the result of the alignment is in sam file format. Such a change would re-
quire redoing the first part of this section of the pipeline as well as part of indexing.
Switching to an aligner which does not output the sam format would require con-
verting the alignment result into sam format so that the samtools and other scripts
would be able to use the alignment result.
3.4 VCPipeline - small variants
Small variants section is for small indels (only few nucleotides) and SNPs. The
workflow for that can be found in figure 3.5. This section produces the most of
the main results of the pipeline. The main inputs are: the reference sequence, the
position sorted binary alignments, the target area, the SNP information table and
the exon position table. Two separate tables are created as result: genotype and
variant. The genotype table has all the previously known SNPs in target area which
were sequenced, while variant table lists all SNPs found in sequencing above certain
quality thresholds. A quality graph is also produced for the SNPs and variants. This
part uses samtools and scripts done for the pipeline.
First for variants, samtools pileup is called to retrieve all differences from
the alignment to the reference. This raw result is then filtered using samtools.pl
varFilter and selections based on the quality values. The result is then reformatted
into a table as a result for the user as well as to draw graphs from. This conversion
is done with pileup2graph.pl. This script reformats the pileup commands output,
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Variant
plot
Samtools
pileup
Samtools.pl
varFilter
pileup2graph.pl Plot_pileup.r
Target
area
SNP
information
Sorted
alignment
Reference
sequence
Variant
table
Exon
position
pos2pileup.pl
Genotype
table
Samtools
pileup pileup2graph.pl
plot_variant_
quality.r
SNP 
quality plot
Figure 3.5: Steps of the pipeline to find small variants.
and allows additional filtering to be done based on read depth and quality ratio from
the sum of quality between variant and reference bases (by default depth requirement
is 10 and ratio should be 0.8 where 1 is reference).
Finally for the variants, the plot pileup.r is executed. It creates a pdf with a
graph showing call depth, call ratio and quality ratio for each entry in variant table.
The call depth is the amount of reads covering the entry. Quality ratio is the same
as described above and call ratio is the ratio between variant and reference calls.
This result can be used for a simple overview for assessing the quality of the SNPs.
Then the genotype table is created. It uses the SNP information table to find all
positions of SNPs in the target area of the reference with a pos2pileup.pl script.
The result is then given to samtools pileup which retrieves those positions from
the alignment regardless of whether it differs from the reference or not. The results
are then converted to a table with pileup2graph.pl as before, but this time without
any filtering.
Lastly a quality graph of the variants as well genotypes are done. The file is
produced from variant and genotype tables producing a file with two plots using
plot variant quality.r script.
If the SNP information or target area positions are not given by the user, the
genotype part is not executed. The quality graph is done but with only the variant
plot.
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3.5 VCPipeline - coverage
Samtools
view
Target
area
Sorted
alignment
sam2gff.pl
count_per_item.pl
Read
Coverage
Overall
Countscounts.pl
Alignment
target_coverage.pl plot_target_coverage.r
Coverage
Graph
Read
Coverage
Heatmap
Figure 3.6: Steps of the pipeline to get coverage and statistics from reads alignments.
The coverage section counts some basic statistics from the alignment. In addi-
tion, it produces two files which have the coverage of reads and graph showing the
quality of the coverage in target areas. It uses samtools to get the data and the
scripts done for the pipeline. Workflow is seen in figure 3.6.
First, the reads which were aligned to the reference are separated out. This is
done with samtools view command. It reads in the position sorted binary align-
ment file and prints out in sam format only the reads which were aligned against the
reference. From this, two different things are done: coverages of reads and targets
and statistics counting.
The counts start with the counts per item.pl script. It prints out the count
statistics per sequence item in the reference. In addition, it produces a coverage file
and a heatmap table which has the amount reads in any individuals target area. The
script uses an index file created earlier in indexing phase and takes in a minimum
fold coverage value, meaning that at least that many reads should cover a nucleotide
for it to be considered (by default 5). The tool counts both one fold coverage and
the user given fold coverage. Then counts.pl combines these results and prints out
overall statistics.
The read coverages are printed in two separate formats. First format is done with
a sam2gff.pl script. It converts the reads into a static window size (by default 50)
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and counts how many times that is covered by reads. The format of the result is
gff. Second is done with counts per item.pl script which was explained above.
The resulting file is in bedgraph (BedGraph Track Format, 2010) format which has
coverage for all positions. The bedgraph coverage file is then compared to the target
areas with target coverage.pl. This script groups the windows with similar score
and prints out the counts of the windows in the groups. The result is a table from
which plot target coverage.r script draws the graph which shows the overall
target area coverage.
3.6 VCPipeline - larger variants
Figure 3.7: Steps of the pipeline to find larger variants.
In order to find the larger variants, a program called pindel (Ye et al., 2009) is
used. Workflow is shown in the figure 3.7.
Pindel uses as an input those read sequences of which the mate is aligned to
the reference and the read itself is not. In order to get these reads, a script
sam2pindel.pl is executed. It goes through the alignment result and prints out
the reads described above. Then the pindel is run. It gives out three files which de-
termine different sorts of larger variants: deletions, insertions and special deletions
with non-template insertion around break points.
3.7 VCPipeline - de novo assembly
De novo assembly is done with velvet (Zerbino and Birney, 2008). The aim however
is not to do a full assembly of all the reads. Instead the reads which were not aligned
to the reference are used here. Any of the assembled contigs could then be used to
search with blast or similar algorithm from a general sequence database to see if
something interesting could be found. Note that this section is only run if there is
less unaligned reads than the number given by user.
First, the reads which were not aligned to the reference are taken from the
alignment with sam2velvet.pl and printed out as set of fasta format sequences.
This set of reads is then pre-processed with velveth for assembly. Finally, the
22
Chapter 3. Materials and Methods
Figure 3.8: Steps of the pipeline to do de novo assembly.
contigs are assembled with velvetg. This takes in the median length between the
reads and minimum contig size given by the user. The result is a set of assembled
contigs of given minimum length.
3.8 VCPipeline - paired-end anomalies
Figure 3.9: Steps of the pipeline to find paired-end anomalies.
The paired-end anomalies are visualised with circos (Krzywinski et al., 2009).
The aim in this section is to find larger groups of sequence pairs which are unusually
paired. This means that they are too far apart in same chromosome or even in
different chromosomes.
First, the pairs which were aligned anomalously are retrieved from alignment
with sam2circos.pl. This script finds all pairs which have ends in different sequence
entries in reference or farther than given value (default 3000) nucleotides apart in
same sequence entry. There is an option which defines the minimum amount of
overlap in order to draw that pair (by default 3). The resulting pairs are written in
given directory with a file for each sequence entry in the format required by circos.
Each file has the pairs of which either end of the pair is in that reference entry
and there is at least minimum amount of overlap as defined earlier. Next, each of
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the sequence entry files are converted into gff files with circosin2gff.pl. The gff
tracks created are not sorted.
Finally, the circos-run.sh is executed. The script runs circos for each se-
quence entry which creates a picture from that entry. The result shows the approx-
imate position in items where the overlapping reads start and end. The thickness of
the line depends on how many reads overlap. The result for an entry has all pairs
which have one end on that item so each pair is showed twice from both ends if it
goes from one item to other.
3.9 Exome kits
The modifications to the manufacturers’ recommended protocols were done in order
to allow additional QC measures between the steps and to remove unnecessary
differences between the protocols.
3.9.1 Nimblegen SeqCap EZ
The samples were prepared mostly according to the SeqCap EZ protocol (Nimblegen,
Exome protocol, 2010) and illumina paired-end protocol (Illumina, PE sample prep,
2010), which is referred by the SeqCap EZ protocol. The modifications to the
protocol are listed below.
Sample preparation, Illumina guide
The DNA was fragmented using Covaris S2 (Covaris, MA, USA) with Covaris mi-
croTubes with AFA fiber. The following setting were used in fragmentation: duty
cycle 10%, intensity 5, cycles per burst 200, time 180 seconds, set mode frequency
sweeping.
The sample preparation kit was changed from Illumina Paired-End Genomic
DNA Sample Prep Kit to NEBNextTMDNA Sample Prep Master Mix Set 1 (New
England Biolabs Inc, MA, USA). This would affect following sections in illumina
paired-end protocol: perform end repair (page 16), adenylate 3’ ends (page 18) and
ligate adapters (page 19).
The quality, quantity and the size of the sample libraries were verified with
Agilent Bioanalyzer DNA1000 kit (Agilent Technologies Inc, CA, USA) after steps:
perform end repair (page 16) and ligate adapters (page 19).
In ligation, 25 pmol of adapters were used. 200 - 300 base pairs were cut from
gel.
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SeqCap Ez guide
Chapter 4. sample library amplification using LM-PCR. 24 pmol of both primers
and 20 ng of sample DNA were used in the PCR reaction. The PCR was run total
of 8 cycles with 4 reactions per sample.
Chapter 7. captured DNA amplification using LM-PCR. 100 pmol of both
primers and 4,5 pg of sample DNA were used in the PCR reaction. The PCR
was run total of 14 cycles with 6 reactions per sample.
After capture the concentration was measured with a qPCR. A 2-fold dilution
series of the standard was used to obtain a standard curve ranging from 50 pM to
1,56 pM. The qPCR was performed with Finnzymes DyNAmo SYBR Green master
mix (Finnzymes Oy, Espoo, Finland) using 10 pmol of primers.
Chapter 8. Measurement of Enrichment Using qPCR. Following areas were used
as targets in this: NSC-0237, USF1 exon, NSC-0272, JMY exon, Chr16 cons. The
primers for these areas can be found from appendix B.
3.9.2 Agilent SureSelect Human All Exon Kit
The samples were prepared mostly as the SureSelect protocol specifies (Agilent,
Exome protocol, 2010). The modifications to the protocol are listed below.
Sample preparation
The NEBNextTMDNA Sample Prep Master Mix Set 1 sample preparation kit was
used instead of Illumina Paired-End Genomic DNA Sample Prep Kit. This would
have an effect in Steps 4 - Repair the ends, 6 - Add ‘A’ Bases to the 3’ end of the
DNA fragments and 8 - Ligate the paired-end adapter.
Step 1, Shear DNA, page 16. The shearing was done with Covaris S2. The
settings differ from of the protocol with time set to 180 seconds.
Step 8, Ligate the paired-end adapter, page 23. 25 pmol of adapters were used
in the ligation.
Step 11, Amplify adapter-ligated library, page 27. 24 pmol of both primers and
20 ng of sample DNA were used in the PCR reaction. Also, the PCR was run total
of 8 cycles with 4 reactions per sample.
Step 13, Assess quality and quantity with Agilent 2100 Bioanalyzer, page 29.
The concentration was measured with Bioanalyzer and based on the analysis, 500
ng of sample was used for capture.
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Post-Hybridization Amplification and Cluster Station Preparation
After the capture the concentration was measured with a qPCR. A 2-fold dilution
series of the standard was used to obtain a standard curve ranging from 50 pM to
1,56 pM. The qPCR was done with Finnzymes DyNAmo SYBR Green master mix
using 10 pmol of primers.
Step 1, Amplify the captured library, page 42. Based on the qPCR result above,
the PCR used 11,5 pg sample per reaction and 50 pmol of primermix. PCR was
then run 16 cycles and 6 reactions per sample.
The result of the PCR was then verified with enrichment qPCR. Following were
used as targets in this: NSC-0237, USF1 exon, NSC-0272, JMY exon, Chr16 cons.
The primers for these areas can be found from appendix B.
3.9.3 Illumina Human 660 Quad chip
The quality of the variant pipelines variant calling was evaluated using a Illumina
Human 660 Quad SNP-chip (Illumina SNP chip). The sample used in the exome
comparisons was earlier genotyped using the Illumina chip according to the manu-
facturers protocol. Genotypes were called using GenomeStudio (Illumina software)
and clustered with other samples not used in this thesis. SNPs with genotyping
success rate under 95% were excluded from the analysis.
There are 592426 SNPs with proper success rate on the Illumina 660 chip, of
which 555675 were mapping to a unique position in the human genome.
3.10 The pipeline configuration for exome comparison
The analysis is based on two runs of both exome kits. First run was done with 60
bp read lengths and second run with 82 bp read lengths. In addition to running the
pipeline for each run separate, the alignments of both runs were combined for both
kits and pipeline was run for the combination.
The combination of the alignments was done with the samtools merge com-
mand. The sorted binary alignment file was merged from run 1 and 2 to create a
sorted file for combination. This was then sorted with samtools sort and format-
ted to textual sam format with samtools view command. The pipeline was then
run without alignment section using the alignment files created as input.
The pipeline was run against the current human genome, the GRCh37 (also
known as hg 19). This was downloaded from ensembl (Hubbard et al., 2009). The
SNP information file was created from data downloaded from ensembl version 57
human variation version 37a, which has imported the variants from dbSNP (Sherry
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et al., 2001) version 131. The exon position file was created from data downloaded
from ensembl version 57 using biomart web API (Smedley et al., 2009).
Tool versions used in the pipeline is listed in table 3.4. The x86 version of binary
was used if available.
Table 3.4: External software
List of all the external software used in the analysis and their respective versions.
Program Version
bwa (Li and Durbin, 2009) 0.5.7
circos (Krzywinski et al., 2009) 0.52
pindel (Ye et al., 2009) 21st of August 2009
samtools (Li et al., 2009) 0.1.7
velvet (Zerbino and Birney, 2008) 0.7.58
The configuration of the options in pipeline are listed in table 3.5.
Table 3.5: Configuration options
The pipeline configuration options used in the pipeline for exome comparisons. The
options which did not affect the results (threading, input file names and sample
name) are not listed. The emphde novo max reads option was in first tests 6000000
and then in later executions 0. This is due to memory issues related with the tool
which weren’t solved by this option.
Option Value
contig size 200
minimum depth 10
coverage depth 20
quality limit hom 0.3
quality limit het 0.8
circos overlap 4
de novo max reads 6000000 / 0
Lastly, an external datafile was used in the comparisons. First was the CCDS
exon set for hg19 downloaded from NCBI website June 4th 2010. This was used to
calculate mean coverages for genes and exons.
A major part of the exome comparison is based on the target files. There are
several target sets for both Nimblegen and Agilent exome kit. See below for name
and description of each of the target files.
Given targets
Both the Nimblegen SeqCap Ez and the Agilent SureSelect has their own target
area coordinates. For Nimblegen the file with the target area coordinates for hg 19
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reference was available after request. This file had 197216 target areas. However for
Agilent kit only the hg 18 coordinates were available. These were converted to hg
19 using Galaxy (Blankenberg et al., 2010) lift-over tool. This conversion resulted
into loss of 8 of the original 165637 target areas leaving 165629 areas.
Given target areas were combined if there was overlaps between areas to prevent
any area from being within each other and sorted accordingly to the requirements in
section 3.1 on page 13. This leaves for Agilent 165571 target areas and for Nimblegen
176817 target areas.
Given targets with flanks
In addition to the targets themselves, targets with 100 bp flanking sequences were
used as well. The aim here is to see how the coverage of the target area tails. This
sized flanking sequences were also used in a presentation by Agilent of their exome
kit.
CCDS targets
The consensus coding sequence exome set was selected as a reference exome. This
is because both Nimblegen and Agilent aim to target the CCDS exome. The CCDS
used is the UCSC (University of California Santa Cruz) CCDS track for hg 18. Hg
18 was selected as it is what the Agilent and Nimblegen used to create the sets and
thus it should have more in common with the both Nimblegen and Agilent targets.
After downloading the track with galaxy, it was converted to hg 19 using the
lift-over tool and merged in a similar fashion as the target sequences above. The
original hg 18 track included 196317 areas. After the above conversion the resulting
file included 163627 areas.
Common targets
While both Nimblegen and Agilent aim to target the CCDS exome, neither do this
completely. In addition, both had targets which were not in CCDS. Because of this
an additional reference set was taken into use in addition to the CCDS reference set.
This is called a common targets set.
Common targets were created by overlapping the CCDS with both Nimblegen
and Agilent target areas. If both Nimblegen and Agilent target area covers a part of
CCDS target, then the area of the CCDS target was included. Note that the actual
manufacturers areas do not need to intersect in this situation. For those targets
areas within both Nimblegen and Agilent sets which did not match a CCDS area,
any intersection was taken.
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Results
The results are divided into two parts. First there is examples of various result files
produced by the VCPipeline. These are divided into two sections: main results and
supplementary results. Second part is the result of the exome comparisons.
4.1 VCPipeline results
The results of the pipeline come from small variants, coverage, alignment, larger
variants, de novo assembly and paired-end anomalies sections. Of these, the align-
ment, small variants and coverage sections provide the main results while larger
variants, de novo assembly and paired-end anomalies sections provide the supple-
mentary results.
4.2 Main results
4.2.1 Small variants
Small variants produce the main results with regards to the variants. There are ta-
bles showing the variant information and three graphs showing the overall qualities.
There are four separate tables for variants.
All the single nucleotide polymorphisms identified from the alignment are listed
in the file variant table.csv. This list is filtered with quality checks and also with
user given requirements. They are compared to list of known SNPs in dbSNP and if
the position matches known SNP, then user is informed of it. Those variants which
are in target are flagged and also SNP is flagged if the change is same as in known
SNP. Example of this file is in table 4.1. The difference between Call base and VCP
call base is that VCP call base is done using quality ratio by conversion script, while
Call base is original call done by the samtools pileup.
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The genotype table.csv file lists all the known SNP locations in given target
area if there was any sequence coverage at that point regardless of the quality. The
format of the table is same as in variant table.
The indel variant table.csv file shows small indels which are found during
alignment. Similar to variants there are quality checks included. These are also
compared to the list of known SNPs and user is informed if there is SNP in the
position of an indel as not all SNPs listed in the dbSNP are in fact single nucleotide
changes but also larger ones including insertions and deletions. Format of the table
is similar to variant table.
As with variants the indel genotype table.csv file lists all the indels in the
target area if such were aligned regardless of the quality values. Format is same as
in variant indels.
In addition, there is graph showing quality of the SNPs in variant table in vari-
ant plot.pdf. It shows call depth, call ratio and quality ratio. Homologous call
(where all the variant calls differs from reference uniformly) should have call and
quality ratios going towards 0 (reference). While for heterogeneous call (where vari-
ant calls are not same but usually divided into two) it should be around 0.5. For
example between 0.35 and 0.65. An example of a this file is in figure 4.1.
Last result from this section is the quality plot.pdf. This file has two graphs
showing a comparison of quality scores. These can be used to see how well the
heterogenous and homogenous variants can be distinguished. One graph is done
from variant and other from genotype table. In perfect data set there should be
three separate clusters shown in genotype plot. Normally however heterogeneous
variants and reference calls don’t separate nicely while some separation can be seen
between heterogenous and homogenous variants. An example is shown in figure 4.2.
4.2.2 Coverage
Coverage has overall statistics output as well as two coverage files in bedgraph and
in gff file format.
The overall statistics of the alignment is in the alignment stats overall.txt.
It gives out several values of how reads are aligned to the target area or into the
whole reference. The result is used to get a simple overview of the quality of the
sequencing. Results show one fold coverage and a user given fold coverage counts
(by default 10). An example of this is shown in figure 4.3.
Second part of the section has two coverage files.
The file that has all aligned reads in gff format is read coverage.gff. Each
reference item is divided into user given window size (by default 50) and each record
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Figure 4.2: Example of a quality plots file. There is two separate plots in the file:
variant and genotype. The variant plot is based on the variant table data while the
genotype plot is based on genotype table data.
The vertical red lines show the heterozygous and homozygous call limits. The calls
in area in the left are homozygous variants. The area in left in variant plot and
between the lines in genotype plot are heterozygous calls. The area in right on
genotype call is reference calls, this area isn’t shown in the variant plot as they are
not considered to be variants.
This example is from the Nimblegen exome comparison data.
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in the gff file is one window. Windows are ordered by their starting point. The gff
score column is used for the coverage within that window. See table 4.2 for example
of the start of the read coverage file.
Table 4.2: The read coverage
The coverage is shown in 50 sized windows of genome with windows of coverage 0
skipped. The file is in gff (GFF specification, 2010) file format. The first column is
the reference item (in this case the chromosome number). Second column shows the
name of the alignment software. Third column has the name of the feature. Fourth
column has the window start position and fifth the end position. Sixth column has
the mean coverage of the window. Seventh and eight columns are not used and
require a dot by specification.
This example is from the Agilent exome comparison data.
1 bwa Agilent read coverage 10001 10050 1.44 . .
1 bwa Agilent read coverage 10051 10100 0.92 . .
1 bwa Agilent read coverage 12101 12150 1.46 . .
1 bwa Agilent read coverage 12151 12200 3.9 . .
1 bwa Agilent read coverage 12201 12250 4.18 . .
1 bwa Agilent read coverage 12251 12300 1.08 . .
Second coverage file coverage.bedgraph is in bedgraph format. It has the
coverage of the entire genome for each nucleotide. An example of the start of the
file is in table 4.3.
Table 4.3: Bedgraph coverage
An example of the start of the bedgraph (BedGraph Track Format, 2010) coverage
file. It shows the coverage of the genome with variable sized sections. First row has
a track line which describes the data behind it. The first column is the reference
item (in this case the chromosome number). The second column is the start point of
a section in referencem, the start position is zero-based so 0 means first nucleotide.
The third column is the one position after the end point of a section. The last
column has the coverage of the section. This example is from the Agilent exome
comparison data.
track type=bedGraph name=coverage
1 0 12104 0
1 12104 12109 1
1 12109 12118 2
1 12118 12119 3
1 12119 12152 4
1 12152 12161 5
1 12161 12168 4
The target coverage.pdf file has a graph which shows the percent of the cov-
erages in the target areas. It can be used to quickly see how good coverage within
the target areas can be expected. An example of this graph is shown in figure 4.4.
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Reads mapping to reference: 91.00% (30398419 / 33403496)
Reference coverage: 12.02% (372032695 / 3095693983)
Reference 10-fold coverage: 1.21% (37398727 / 3095693983)
Target coverage: 91.57% (34455223 / 37627190)
Target 10-fold coverage: 63.61% (23935333 / 37627190)
Reads mapping to target (of mapped to reference): 60.93% (18521684 / 30398419),
(of all): 55.45%
Figure 4.3: An example of the alignment counts. The numbers in brackets are as
follows. In first line, reads mapped to the reference divided by all reads in alignment.
In second line, number of nucleotides covered by at least one read divided by all
nucleotides in the reference. In third line, number of nucleotides covered by at
least 10 reads divided by all nucleotides in the reference. In fourth line, number of
nucleotides covered by at least one read in the target areas divided by all nucleotides
in the target areas. In the fifth line, number of nucleotides covered by at least 10
reads within the target areas divided by all nucleotides in the target areas. In the
sixth line, number of reads at least partially in the target area divided by all reads
mapped to the reference. This example is from the Agilent exome comparison data.
Figure 4.4: The example plot shows a part of the target coverage. The y-axis is
percent of the nucleotides and x-axis has the fold coverage groups. The coverage
groups are counted per 5 nucleotide, so 0, 1-5, 6-10 etc. The vertical red line shows
the largest group. Only up to 400 depth is shown in the actual graph. This example
is from the Agilent exome comparison data.
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The last result from the coverage section is heatmap.csv file. It has a simple
table showing the amount of reads at least partially within it for each target area.
This can be used to compare several samples if there is noticiable differences in the
read amounts per target and if some targets are completely missing from some of
the samples. An example of this graph is shown in table 4.4.
Table 4.4: Heatmap table
An example of the start of the heatmap table. First column is the reference item
name (in this case chromosome number). Second and third columns are start and
end of the target area respectively. Fourth column has the number of reads at least
partially in the target area. This example is from the Agilent exome comparison
data.
1 30276 30395 430
1 69070 70029 3078
1 367648 368607 2408
1 621085 622044 2233
1 861298 861417 6
1 865533 865745 1
1 866384 866503 10
1 871094 871333 8
1 874405 874524 5
1 874628 874867 4
4.2.3 Alignment
There are two results from this section. One is the alignment file itself and then the
other is result of filter B.pl script.
The alignment file is in sam file format. It has all the reads and their aligned
positions in the genome. The alignment file is very large, usually over 10Gb, so it’s
rarely viewed directly and thus no example of it is provided.
The filtering result shows how much from the initial input is filtered out due to
quality scores. If in the end of the read there is a block of B quality scores, then
the read is trimmed to remove them. If the read length drops below user given limit
then the read pair is removed. An example is shown in figure 4.5.
Pairs in: 32455200
Pairs out: 31159095 (96.01%)
Trimmed reads: 9512789 (15.26%)
Figure 4.5: Example of filter B.pl result. The script removes section of sequence
from the end of the read if the quality score for those nucleotides is B. The first line
has the count of read pairs in input. Second line has the read pairs for output with
percentage in brackets. Third line has the number of reads which were trimmed
from end with percentage in brackets (from the output reads).
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4.3 Supplementary results
4.3.1 Large Variants
The large variants produce three files which show various larger variations and their
supporting information. The three files created have following types of variations:
insertions, deletions and special deletions with non-template insertion around break
points. The format is pindel native format. An example of one of the result files is
in figure 4.6.
4.3.2 De novo assembly
The de novo assembly creates a file with assembled contigs. The minimum size of
the contigs is given by the user. The file corresponds to the fasta format where on
header line there is the node number, length of the contig sequence and coverage of
the assembled contig. See figure 4.7 for an example. The result is created in its own
subdirectory and in addition there is supporting files which can be looked into for
more information.
>NODE_12_length_180_cov_4.200000
GAACCGCTCTTCCGATCTTTTAATCAGATGATGGTGGTGCTACCCCAGTACAGGATGAAC
GGGATTCAGGGTCAGACGGTGAGGATGATGTAAATGAGCAACACTCCGGATCAGACACTG
GAAGTGTAGAACGTCATTCAGAGGTATTGGCTAACCAACATCTTTGGGAGGGCTTTTCCC
TTGCGTTCTGTGAGATCTGTTATA
>NODE_53_length_228_cov_47.285088
GTTGTTTTCTAGCAGTGACAAGTTCACTTTGAATCAGGTTTGAACTTGACAATTTACTGT
CTTCCTCATTGAATTCCTCCTTGCACATTTCTGCTTTATCTCATCTACACAGAAGTGATC
CAATATTTAGCTATAGAGCTATATTAGTTAAGAAGGTATTTTTAAAGTAAAATTTGTAGG
TTTTTAGCTTAGTCTCCATTTAAAATATGTTCTGTTTTCTTAACTTCAGGATATGTGTGT
AGTTTGTGGCAG
Figure 4.7: A start of an example result of the de novo contig assembly. The
assembled contigs are in fasta format. The contigs are assembled from read sequences
which were not aligned to the genome. This example is from the Agilent exome
comparison data.
4.3.3 Paired-end anomalies
The paired-end anomalies section produces pictures and gff tracks.
In picture there is a circle with green sections showing different reference sequence
entries, which in case human genome would most likely be chromosomes, with red
lines starting from the entry for which the picture is drawn. Each red line represents
multiple pairs of reads, which overlap each other, pairing anomalously within the
genome. Either the pairs’ ends are in separate reference items or too far apart within
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Figure 4.8: Example of the anomalies drawn by Circos (Krzywinski et al., 2009) from
paired-end alignment. This is for the reference sequence entry named ’1’ (meaning
chromosome 1), which can be seen from the picture as all the lines have one end
in entry 1. Each line represents a multiple overlapping pairs of reads which start
from one chromosome and end in other or are too far apart of each other in same
chromosome. The thickness of the red line is relative to the amount of overlapping
read pairs. This example is from the Agilent exome comparison data.
the same reference item. The thickness of the line is relative to the amount of pairs
in the anomaly. An example of the Circos plot is shown in figure 4.8. Anomalies
shown in picture can be artefacts of the sample preparation, sequencing or possibly
true translocations or larger deletions. The anomalies result can also be used to
detect possible sequence input mistakes and mixups.
The gff files then show more detailed information. For each of the reads exact
position, how many other reads overlap that read and the position of the pair is
described. See example in table 4.5.
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Table 4.5: The anomalous pairs
The first column is the reference item (in this case the chromosome number). Second
column shows the name of the alignment software. Third column has the name of
the feature. Fourth column has the window start position and fifth the end position
of this end of the read pair. Sixth column has the amount of overlaps that this read
has. Seventh and eight columns are not used and require a dot by specification.
Ninth column has the start and end position of the other end of the pair as well as
the read pair name (which is removed from below). The rows are in pairs so the
other end of the pair is in next row.
This example is from the Agilent exome comparison data.
1 bwa set1-agilent odd paired 8716175 8716233 3 . . 22567021, 22567079:
15 bwa set1-agilent odd paired 22567021 22567079 3 . . 8716175, 8716233:
1 bwa set1-agilent odd paired 8716178 8716236 3 . . 22567022, 22567080:
15 bwa set1-agilent odd paired 22567022 22567080 3 . . 8716178, 8716236:
1 bwa set1-agilent odd paired 8716182 8716240 3 . . 22567014, 22567072:
15 bwa set1-agilent odd paired 22567014 22567072 3 . . 8716182, 8716240:
4.4 Exome comparison results
This section presents the results from the exome comparison.
4.4.1 Reads
The amounts of reads in each run at various stages are listed in table 4.6. The
amount of nucleotides are not listed for each step as filtering done in alignment
(filter b.pl script in section 3.3 page 18) can trim the read.
Table 4.6: Read counts
The table lists how many reads were produced and aligned. Produced - the number
of reads produced by the Illumina software. For alignment - the number of reads
that are input to the alignment after all the filtering is done. Aligned - the number
of reads which are aligned into the reference sequence. On target - the number of
reads of which at least one nucleotide is within the target area.
Manufracturer Run Produced For alignment Aligned On target
CCDS Own
Agilent Run 1 35426712 31027419 29945945 15883486 18147078
Nimblegen Run 1 37662148 30742570 30665305 20957572 24844142
Agilent Run 2 59817166 52304467 46956740 26715060 29697854
Nimblegen Run 2 64910400 53080289 52671092 39343229 44455439
Agilent Comb 95243878 83331886 76902685 42598546 47844932
Nimblegen Comb 102572548 83822859 83336397 60300801 69299581
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4.4.2 Coverage
Coverage section deals with coverage across the targets and genes. Only some results
of the pipeline are shown. Others are derivates showing the comparisons.
The coverage values from both sequencing runs show Nimblegen preforming more
efficiently, meaning larger percentage of reads align against reference, with larger
amount of target having 20 fold coverage. This is shown in all targets. As an
example the figure 4.9 shows a counts file from both Agilent and Nimblegen using
CCDS target. A graph showing the 20 fold coverages of all target areas for both
kits is shown in figure 4.10.
a
Reads mapping to reference: 89.78% (46956740 / 52304467)
Reference coverage: 19.42% (601219016 / 3095693981)
Reference 20-fold coverage: 1.21% (37427019 / 3095693981)
Target coverage: 92.61% (25763572 / 27819612)
Target 20-fold coverage: 60.71% (16889307 / 27819612)
Reads mapping to target (of mapped to reference): 56.89% (26715060 / 46956740),
(of all): 51.08%
b
Reads mapping to reference: 99.23% (52671092 / 53080289)
Reference coverage: 9.94% (307803672 / 3095693981)
Reference 20-fold coverage: 1.23% (38102971 / 3095693981)
Target coverage: 89.93% (25017284 / 27819612)
Target 20-fold coverage: 66.58% (18523002 / 27819612)
Reads mapping to target (of mapped to reference): 74.70% (39343229 / 52671092),
(of all): 74.12%
Figure 4.9: Exome comparison counts result. The two examples are from the results
of the sequencing run 2 with CCDS target area. Figure (a) is from Agilent and (b)
from Nimblegen.
To see how the targets are covered in more detail a graph can be done from
target coverages. This will show how balanced the target coverages are in both.
The CCDS and the kits’ own targets were used for this. The resulting graph is
shown in figure 4.11.
In order to get coverage of known genes, the datafile with CCDS exons was used.
That was then combined with the bedgraph coverage files from each sequencing run
to produce mean coverage of all genes in each of the runs. The resulting genes were
sorted according to the coverage and plotted to show the overall view on how well
the genes are covered. The plot can be seen in figure 4.12.
The files created above were then used to gather the amount of transcripts com-
pletely covered with various fold coverage. For transcript to count completely cov-
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a b
Figure 4.10: Counts comparison graph. The bars show the percentage of target
areas covered within the sequencing runs. Target areas are as follows: own - kits’
own target, flank - kits’ own target with 100 bp extra on both flanks, common -
areas which is shared between the kits and CCDS - ccds (Pruitt et al., 2009) exons.
The blue coloured bars are for Nimblegen and red coloured bars for Agilent. Figure
(a) has one fold coverage while figure (b) has 20 fold coverage.
ered, all exons within the transcript had to have the required coverage. This was
done for combined coverage of both runs for both kits. In total there was 23746 tran-
scripts in the CCDS file. The list of transcript coverages can be seen in table 4.7
Similarly we can go through the exons and see how many of them are covered
with various fold coverages. There is total of 185508 unique exons in the CCDS file
(after removing the exons which were in different transcript but in same position as
another exon), of which Nimblegen covers 133546 exons and Agilent 120923 exons.
Of these, 108466 exons are shared. This means that Nimblegen has 25080 unique
exons while Agilent has 12457 unique exons. The list of exon coverages can be seen
in table 4.8.
Heatmaps can also be used to see how similar the kits are. Using the common
and ccds target we can compare the areas which both Nimblegen and Agilent should
cover. Since the read amounts fluctuate between sequencing runs, the comparison
of read counts does work directly. By counting areas with no reads we should see
equal number of deletions as long as the target should be covered. With common
target, there is 2634 target areas with no reads in Agilent and 606 in nimblegen.
Of these 528 are same. This leaves 2106 unique areas with no reads in Agilent and
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Table 4.7: Transcript counts
The table lists the count of transctripts completely covered by a required coverage.
The transcripts were taken from CCDS (Pruitt et al., 2009). The coverages were
counted from the combined data.
Manufracturer Coverage Transcript count Transcript %
Agilent 20 6621 27.88
Nimblegen 20 9652 40.65
Agilent 10 8899 37.48
Nimblegen 10 12686 53.42
Agilent 5 11273 47.47
Nimblegen 5 15168 63.88
Agilent 1 16201 68.22
Nimblegen 1 18134 76.37
Table 4.8: Exon counts
The table lists the count of exons covered by a required coverage. The transcripts
were taken from CCDS (Pruitt et al., 2009). The coverages are counted from the
combined data.
Manufracturer Coverage Exon count Exon %
Agilent 20 120923 65.18
Nimblegen 20 133546 71.99
Agilent 10 136627 73.65
Nimblegen 10 143062 77.12
Agilent 5 148064 79.81
Nimblegen 5 148083 79.82
Agilent 1 163249 88.00
Nimblegen 1 153927 82.98
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78 in Nimblegen. With CCDS target, there is 3481 target areas with no reads in
Agilent and 11219 in Nimblegen. Of these 1056 are same. This leaves 2425 unique
target areas with no reads in Agilent and 10163 in Nimblegen.
4.4.3 Variants
With variants most comparisons are done with the combined dataset. The compar-
ison are done between the variant table listing the found variants or genotype table
listing all the known variant positions. In addition, the quality is evaluated with
external SNP-chip using the genotype calls created by using the Illumina Human
660 Quad chip.
First the found variants are compared.
First we compare the methods against a suitable reference to see how much
difference there is in variant calling between them. For this the CCDS and common
targets are suitable. CCDS because the target which is the aim for both kits and
common because that is the area where their targets actually overlap. Within the
CCDS targets, there were 12547 variants identified by the Agilent capture and 13406
by the Nimblegen capture. A total of 10526 variants were in the same position. This
means that Agilent identified 2021 (16.11%) and Nimblegen 2880 (21.48%) unique
variants within the CCDS target area. For the common target area, the Agilent
identified 11326 and the Nimblegen 13444 variants. 10571 of those were in the same
position. So Agilent identified 755 (6.67%) and Nimblegen 2873 (21.37%) unique
variants within the common target area.
Next the SNP calls were compared with genotypes produced by using the Illu-
mina SNP-chip. Of the SNPs represented on the chip, 7381 positions were covered by
the sequences obtained from the Nimblegen capture and 7464 from the Agilent cap-
ture with a minimum of 10 fold coverage. From these positions, the chip was unable
to make the call in 184 sequenced by Nimblegen and 224 sequenced by Agilent. 7438
(99.65%) of the VCP calls from the Nimblegen capture agreed with the genotype
call from 660 chip, while the numbers were 7321 (99.18%) for the Agilent capture.
Further, 5899 SNP were covered by all three methods. Of these VCP calls from
Nimblegen and Agilent captures agreed on 5862 (99.37%) SNPs, and 5710 (97.41%)
of them also agreed with genotyped call. Of the 37 discrepant calls between the two
capture methods, 21 of the Nimblegen capture derived calls agreed with genotype
call while the corresponding number for Agilent capture was 12. Chip was unable to
call 4 of those. Differences between the two kits were whether the call heterozygous
or homozygous.
Then the known variant positions are compared.
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There are 156811 known variants in the CCDS target. Of these there are 153284
within the Agilents own target area and 134391 within the Nimblegens own target
area. With a minimum of 10 fold coverage Agilent has 115188 SNPs (75.10%) and
Nimblegen has 123498 (91.19%) SNPs sequenced.
From the own targets of the Agilent and the Niblegen, there were 158604 known
variant positions within both capture methods. Within these positions they agree
on 149757 (94.42%) positions. Of these Agilent has 126698 (79.89%) positions and
Nimblegen 146671 (92.47%) positions with at least 10 fold coverage. With the
minimum coverage of 10 there is 117188 same calls.
Then the SNP calls were compared to Illumina SNP-chip. From chip, 9691 SNP
positions were covered by the sequences obtained from the Agilent capture and 9803
SNP positions from the Nimblegen capture with minimum of 10 fold coverage. Chip
was unable to call 384 positions sequenced by the Agilent and 369 sequenced by
Nimblegen. 9115 (97.94%) of the VCP calls from the Agilent capture agreed with
genotype call from the 660 chip, while the Nimblegen agreed with 9194 (97.46%)
calls. Further, 7826 positions were covered with all three methods. Of these VCP
calls from Nimblegen and Agilent captures agreed on 7509 (95.95%) SNPs, and 7215
(92.19%) of them agree with genotyped call. Of the 317 discrepant calls between
the two capture methods, 128 of the Nimblegen capture derived calls agreed with
genotype call while the corresponding number for Agilent capture was 166. Chip
was unable to call 20 of those and in 3 cases all methods gave different result.
Then as last part of this section, some comparison are done between the runs
of the same method to try to see how stable the sequencing results are. There was
28386 SNPs found Agilent on the run 1 and 42166 on the run 2 with minimum of
10 fold coverage. Of these, 25655 (90.38% from run 1) were in both. The 2731
SNPs which are missing from run 2, 2068 (75.72%) were not covered with 10 fold
coverage. The remaining 663 were not called by default. When manually retrieved
and called 376 (13.77%) were same and 287 (10.51%) different. With Nimblegen
there was 29225 SNPs found on the run 1 and 41135 on the run 2 with minimum
of 10 fold coverage. Of these, 26513 (90.72% from run 1) were in both. The 2712
SNPs which are missing from run 2, 2197 (81.01%) were not covered with 10 fold
coverage. The remaining 515 were not called by default. When manually retrieved
and called 238 (8.78%) were same and 277 (10.21%) different. Further details of the
effect of increasing the amount of reads (and lengths) to the variant calling can be
seen in table 4.9.
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Table 4.9: The effects of read amounts to variants
The comparison below is done to show the effect of read amouts with variants. Run
1 provided little over half of the reads of Run 2. Combined has both runs so there is
little under 50% more reads than in Run 2. All calls have minimum fold coverage of
10. The percentages show the increase to previous run counts for the same method.
The found variants are listed in table (a) and the known SNP positions are listed in
table (b).
Run - the run and method. Total SNPs - the amount of SNPs listed. In SNP chip -
count of SNPs which are in SNP chip and sequenced. Genotyped - count for SNPS
which chip was able to call. Same - count which matches the SNP chip genotype
calls
a Run Total SNPs In SNP chip Genotyped Same
Run 1 Agilent 28386 4862 4730 4621
Run 2 Agilent 42166 (149%) 6598 (136%) 6419 (136%) 6384 (138%)
Combined Agilent 49745 (118%) 7587 (115%) 7364 (115%) 7321 (115%)
Run 1 Nimblegen 29225 5320 5232 5146
Run 2 Nimblegen 41135 (141%) 6931 (130%) 6774 (129%) 6661 (129%)
Combined Nimblegen 47805 (116%) 7665 (111%) 7481 (110%) 7438 (112%)
b Run Total SNPs In SNP chip Genotyped Same
Run 1 Agilent 189457 7672 7362 7269
Run 2 Agilent 195662 (103%) 8988 (117%) 8627 (117%) 8532 (117%)
Combined Agilent 200286 (102%) 9691 (108%) 9307 (108%) 9115 (107%)
Run 1 Nimblegen 182651 8370 8101 7988
Run 2 Nimblegen 186860 (102%) 9494 (113%) 9148 (113%) 9044 (113%)
Combined Nimblegen 187828 (101%) 9803 (103%) 9434 (103%) 9194 (102%)
4.4.4 Paired-end anomalies
A selection of paired-end anomalies pictures are collected to figure 4.13. These are a
small but representative selection of what can be seen in the images overall. (a) and
(b) show most anomalies in both. (e) and (f) is an example of multiple situation
where Nimblegen doesn’t show any lines while Agilent does. (c) and (d) are then
example of something in between the two pairs detailed above.
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a b
c d
e f
Figure 4.13: Paired-end anomalies comparison. Each picture represents one chro-
mosome. Each red line represents a multiple overlapping pairs of reads which start
from one chromosome and end in other or are too far apart of each other in same
chromosome. The (a), (c) and (e) are from Agilent and (b), (d) and (f) are from
Nimblegen. The images are from combined data set.
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Conclusions
5.1 VCPipeline results
Overall there is a good set of results to start the further analysis from, as could be
seen in the exome comparison results in section 4.4 on page 40. The main results
include several results from alignment to variations (such as SNPs and indels) and
coverage as well as quality control aids. Supplementary results then extend from
this to few directions (such as trying to recover information from unaligned reads).
Extending the pipeline to give complete results for the user (eg. the person who
ordered the sequencing) can be very difficult as the needs can vary greatly depending
on the project.
In addition to the results for the user, there are several different quality metrics
for the sequencing laboratory. These will help to make sure that there are no false
results given out and may help with further development of methods. Some of the
results are as useful for the user as for the sequncing laboratory. The conclusions
below are considered from the point of the user.
The pipeline described in thesis was designed with an assumption that the se-
quencing produces a one pair of sequence files as a result of single paired-end sequenc-
ing of a single sample. The Illumina GAII sequencer produces a pair of sequence
files for each lane, so the assumption is that each lane has one sample. Thus, the
pipeline handles the basic situation where every lane is separate sequencing event.
However there are two exceptions to this. Multiplexing and merging.
In multiplex situation there is multiple samples in one lane and there is an index
sequence which can be used to separate the samples as explained in section 1.2.2 on
page 6. At the moment there can be up to 12 separate indexes per lane leading to
96 separate samples in the 8 pairs of sequence files produced. While the separating
the samples could be done manually, running the pipeline manually for 96 times is
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not very practical. As an improvement, the pipeline could support multiplexing so
that it has to be executed only once.
Merging is samilar situation, but looked from another direction. In merging a
single sample is sequenced in multiple lanes leading to the need of combining multiple
sequencing results into one. Running pipeline manually in this case would require
running the alignment section multiple times. Then manually merging alignment
results which would then be used as input to the rest of the pipeline. Again to
reduce the manual work this should be supported so that pipeline should executed
once.
5.1.1 Main results
The first files to look in the results are the alignment stats. This file will tell whether
the sequencing and the possible target capture have succeeded. Preferably more than
80% of reads should align to genome in a good result. If the sequencing is a targeted
sequencing, then alignment stats can also be used to confirm that the targeting has
worked. With poor target enrichment, the higher fold coverages are often very low
(for example 20%) for target while proper number of reads have been aligned against
the reference (more than 80%).
The alignment files are the most important result for the user even though some
users might not look at them directly. They present an interesting problem with
regards to visualisation. There is small number of programs which can open the
files as they are multiple gigabytes in size (such as the alignment files). One such
program is the Integrative Genomic Viewer (Broad Institute, IGV). An alternative
would be to setup an account in UCSC Genome Browser (Kent et al., 2002) and
have a local server to serve the data on-demand.
The main tables of interest are the variant table and the indel variant table.
These provide the main results with regards to the variants (SNPs and small indels)
in a tabular format and can thus be used in further analysis. However the pipeline
could be improved to allow some form of visualisation of the variants as well. For
example if alignment is visualised, then the called variations should also be visu-
alised with it to allow the visual inspection to which of the variations shown in the
alignment are also called.
The quality graphs and variant plots are used for quality assessment to identify
potential major skews in variant calling. This part of the pipeline results are mainly
used by the sequencing laboratory before releasing the data to user. This is impor-
tant to user in order to prevent badly created data from being used in analysis and
causing incorrect conclusions.
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Coverages are shown in two different formats. Bedgraph format is more accu-
rate representation of coverage while many locally installed tools might work better
with gff formatted files as it is an older format. Coverage results can be looked in
specificity if there is a gene or set of genes or some other areas of interest to make
sure that those were sequenced properly.
Heatmap table can also be used to make sure that all the target areas were
sequenced. With combination of coverage and heatmap files, the user can try to
detect deletions or other structural variations which would result to deletion of a
target area. The heatmap however only tells how many reads touched the area.
It might be worthwhile to change the format a bit by reporting the amount of
nucleotides the read actually covers instead. This should show more accurate value
of it’s coverage.
5.1.2 Supplementary results
Supplementary sections each provide a single type of result.
For larger variantion there is three separate files which are used to identifying
different kinds of variations. These are an addition to the indel results provided
above and cover larger indels than what the earlier result had. Each of these are
usable by themselves.
Paired-end anomalies result should be used in conjuction with coverage results.
There should not be a large difference in the support of those and coverage at that
position. Currently the score given in the gff entry is half of the support (rounded
down to full integer). This is due to reasons of circos drawing and is something that
should be improved. Additionally, some filtering to these results should be done
to reduce the false positives. For example comparing the positions to coverage and
discarding by user given ratio as at least 25 or 50% of the coverage should be in
anomalies for them to be valid.
Currently the de novo assembly section is mostly turned off in the pipeline (by
setting the read maximum to 0). This is due to reasons of memory use by the
assembler. An assembler, such as ABySS (Simpson et al., 2009), which can be
parallellised should be taken into use. This would help with the memory loads.
5.2 Exome comparison
For final analysis, additional capture experiments and additional sequencing runs
would be needed. The data presented here is based on one capture experiments per
capture method and two sequencing runs. However further experiments with these
capture methods have provided comparable results (results not presented here).
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5.2.1 Reads
The read statistics show that in general Nimblegen capture protocol provides more
reads than the Agilent one, but filtering seems to remove more reads from the Nim-
blegen than from the Agilent. Thus, similar amount of reads enters into alignment.
However for both runs the Nimblegen capture seem to align somewhat more effi-
ciently on the reference and on target areas as can be seen in table 4.6 and the
figure 4.9. After filtering and removing the duplicates both capture methods pro-
vide high quality template libraries as approximately 90% or more of the produced
sequence align to the reference sequence.
5.2.2 Coverage
Since there can be sequencing errors in individual reads a high coverage is needed
for the areas of interest as many errors on same position by multiple reads is highly
unlikely. The results show two separate sets of data within coverage comparisons.
First is the target area comparison and second is gene related comparisons.
Target coverages can be seen in figure 4.10 and graphs of figure 4.11 with regards
to coverage statistics and also in target heatmaps. The coverage statistics show that
Nimblegen captures provide more high coverage data while sequences from Agilent
capture are less concentrated on target areas. The individual statistics indicate that
the Agilent capture covers more of the genome outside of the target than Nimblegen.
Target coverage graphs allow a more detailed look at the target coverages. An
optimal coverage would be approximately A perfect target coverage graph should
have spike with good coverage, for example in between 20 and 50 coverages, and
nothing outside it. Agilent capture methods show a spike in 5 - 10 coverage bin and
also correlates with the lower 20 fold coverage in statistics. This implies that while
some of the probes are very efficient in capturing the genomic DNA, other probes
have perform less efficiently. The heatmap comparison with no reads on common
areas seem to support this as there is more areas with no reads in Agilent than
in Nimblegen. The graphs of the Nimblegen captures does not seem to have any
major spikes and the combined data is more flat any other graph. This is somewhat
unexpected as coverage statistics showed that the Nimblegen provide more areas
with sufficient coverage. Further Nimblegen seems to have a bit larger percentages
in high coverage depths. This can be seen in the run 1 graphs in the target coverage
table. This would imply that Nimblegen has too many probes for areas which get
very high coverage, over 100 fold coverage in this study.
The fact that the Agilent capture method covers more of the CCDS target area
than the Nimblegen can also be seen from the results. The coverage of its own target
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seem to correlate with CCDS unlike with Nimblegen captures. Then in the coverage
statistics the Agilent with one fold coverage has better CCDS target coverage than
the Nimblegen. And finally, in the heatmaps the Nimblegen has much more areas
with no reads.
Second interest of looking at the coverage is to see how well genes and their
products are covered. The results are in two tables: the transcript coverages in
table 4.7 and exon coverages in table 4.8. In addition, there are genes coverage
graphs in figure 4.12.
For genes and transcripts, all the results are showing similar information. The
Agilent is covering more genes with low sequence coverage while the Nimblegen
is covering higher percentage of genes with high coverage. At the exon level the
Agilent is covering more exons with read depth of 1 while more exons are covered
with depth 10 or more with the Niblegen capture method. Gene coverage graph
reflects the exon results. In exons and genes the results show the mean coverage of
the area in question, all exons of the genes are checked counting the mean over all
to get the coverage. However for transcripts, multiple exons are checked separately
to fulfill the criteria and only transcripts which has all exons above the limit are
considered to be covered properly. This might explain the difference in transcript
result where Nimblegen is better even in low coverages. So Agilent capture seems
not to be able to cover all the exons in transcripts even if it covers more individual
exons than the Nimblegen capture.
5.2.3 Variants
There is very little variation between the two methods with regards to the compar-
isons between the CCDS and common targets. Nimblegen has few more variants
in those targets but the difference is not significant. Only noteworthy difference is
when comparing known genotypes. The Nimblegen has over 10% more of known
SNPs than the Agilent. Comparison of SNP posisions which both capture methods
cover has almost no difference (more than 99% are called same).
When doing the quality comparisons against the Illumina SNP-chip there is again
very little difference between the methods. Both methods seem to produce high
quality variants as most calls (more than 95% in all comparisons) which intersect
with chip SNPs are the same. It is noteworthy to mention that both of the the
sequencing methods presented were able to produce variant calls on positions which
the chip was unable to produce a genotype call.
Sequencing runs one and two are not directly comparable in most cases, because
the amount of reads produced as well as size of the reads are much lower with both
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kits on run 1 compared to run 2. Two comparisons are made however. First, to find
out how many of the variants are retained between runs and secondly how many
new variants was found due to increased data.
Since run 2 produced much more sequence, it would be assumed that higher
number of the variants would be retained than in equal sized runs. With both
methods the retain rate of variants between the two runs was about 90%. Most of
those which were lost with both methods were due to not having sufficient depth in
run 2 (over 75% with both). Larger part of those which did have sufficient coverage
were calls which were near the 0.8 quality limit and were called reference. They in
most cases did have same variant bases as in run 1. However in run 2 the quality
of the variant bases were either too low or there was too few variant calls. Many of
those variants were near the 0.8 limit in the run 1 as well. Smaller part of unretained
variants would have been clear variants by only looking at the quality ratio. However
the algorithm which detects the variants before quality filtering is applied, did not
call them for unknown reason.
In addition, the table 4.9 can be used to see how much more variants are called
by increasing the data available. With variants called the differences are quite large
between runs 1 and 2 as it should be. However combining the two runs results
in substantially smaller gains. This is most likely due to the targeting. As both
runs aim to sequence the same area, the saturation in many areas does not give
more information on it. Only the targets with smaller coverage are aided with this.
It also suggests that some of the areas within the targets are very hard to capture
adequately and thus adding more and more sequencing lanes will not help to increase
the coverage of those areas.
There seems to be practically no difference between the two methods in sequenc-
ing accuracy. For variant calling both are equally good. For further validation, a
number of discrepant calls should be sequenced using the Sanger sequencing. The
main effect to variant calling comes from coverage. If user is interested in variations
in some specific genes, then it makes more sense to make sure that the method used
covers the gene in question properly.
5.2.4 Paired-end anomalies
The main intention with the paired-end anomalies is to find translocations. However
since the data being analysed is exome sequencing data, there is little chance of
actually finding them. For exome sequencing to find a translocation, the break
point needs to be in an exon and not in an intron or between genes. Since exome
that these kits sequence is a small part the genome, it is not very likely to show
55
Chapter 5. Conclusions
true translocations. The picture can however be used to see how much noise the
capturing methods produce.
The paired-end anomalies pictures (shown in figure 4.13) show less anomalies for
the Nimblegen capture. Only few images were selected into the figure, but there was
no single pair where Agilent would have had less spreading of the sequence when
compared to Nimblegen. Only chromosome with no lines for both was mitochondria.
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Appendix A
VCPipeline configuration
Example of the configuration file for the VCPipeline.
[files]
# required
reference sequence = file name of reference genome
sequences 1 = first sequences of paired read
sequences 2 = second sequences of paired read
# optional
# target area = gff file with target areas
# snp details = snp file describing snp information
# exon details = exon position file with gene, transcript and protein ids
# optional output directory
# output directory = directory where the output files go
[tool options]
# required
contig size = minimum size for contig in de-novo assembly
sample name = name of the sample, will appear in gff tracks
minimum depth = minimum depth for variant for snp in variant table
# optional
# if quality ratio smaller assume homozygous call
# quality limit hom = 0.2 (default)
# if quality ratio higher assume reference call
# quality limit het = 0.8 (default)
# minimum number of overlaps to include in circos plot
# circos overlap = 4 (default)
# depth for counting coverage stats
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# coverage depth = minimum depth (default)
# minimum read length = minimum length for read after trimming B from
# read end
[workflow]
# if there is more than this many reads, then velvet will not be run
de novo max reads = 6000000
# number of threads done with programs using threading (bwa)
threading = 6
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PCR primers used in post
hybridization
These primers were used to verify the results of the PCR. Same set of primers were
used with both exome kits.
Table B.1: Verification primers
NSC primers are part of the SeqCapEZ protocols (Nimblegen, Exome protocol, 2010)
verification primers while the rest were made for the comparison. The Chr16 cons
is a negative target area. That means that it should not show up in the PCR.
Target area Direction Sequence
NSC-0237 forward CGC ATT CCT CAT CCC AGT ATG
NSC-0237 reverse AAA GGA CTT GGT GCA GAG TTC AG
NSC-0272 forward CAG CCC CAG CTC AGG TAC AG
NSC-0272 reverse ATG ATG CGA GTG CTG ATG ATG
USF1 exon forward GTC GAA GCA CGT CAT TGT CC
USF1 exon reverse GGA GCT TCG GCA GAG TAA CC
JMY exon forward CCG ATA CAG ACC CTC TAA CAC G
JMY exon reverse CCT CTG ACT CTG GGG ATG CT
Chr16 cons forward CTC TTC AGA AAG TGC TAC ACA AGC A
Chr16 cons reverse GCT GAG GCT ACC TAG AGA CAT TGA TTA
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